Salute e Benessere

Bavarian Nordic Announces Closing of Sale of Priority Review Voucher and…

COPENHAGEN, Denmark, July 31, 2025– Bavarian Nordic A/S (OMX: BAVA) today announced the completion of the sale of its Priority Review Voucher (PRV). Upon completion, the company received a cash consideration of USD 160 million.Seecompany announcement no. 18/2025for additional information about the PRV sale.After deduction of royalties to the National Institutes of Health and transaction costs, the net proceeds amount to DKK 810 million, which will be recognized as other operating...
Nasdaq GlobeNewswire
31/07/2025

Cell Culture Market worth US$50.69 billion by 2030 with 11.2% CAGR |…

Browse in-depth TOC on "Cell Culture Market" Browse in-depth TOC on "Cell Culture Market" 999 - Tables 57 - Figures 764 - Pages By products,the cell culture market is segmented into consumables and equipment. Consumables are further segmented into sera, media, reagents; vessels; and accessories. Equipment is further categorized as bioreactors, storage equipment, and other equipment. The consumables segment dominated the market in 2024 and is expected to grow at a higher...
PR Newswire
31/07/2025

PureHealth Delivers Strong H1 2025 Results with AED 13.6 Billion in Revenue and…

As part of its continued evolution and transformation of acquired assets, PureHealth is streamlining its operating model built around two core verticals: Care and Cover. This structure brings together all Group businesses under each vertical, with 'Care' encompassing Hospitals, Procurement, Diagnostics, and Technology, while 'Cover' includes the Group's Insurance operations. The new model strengthens PureHealth's ability to deliver coordinated, value-driven services by aligning care delivery…
PR Newswire
31/07/2025

Glaucoma Treatment Devices Market Set to Surge from USD 4.5 Billion in 2024 to…

This growth is attributed to the rising burden of glaucoma worldwide, increasing adoption of advanced surgical interventions, and improved accessibility to ophthalmic care. Expanding healthcare infrastructure and ongoing innovation in treatment technologies are further enhancing market size and investment potential. This growth is attributed to the rising burden of glaucoma worldwide, increasing adoption of advanced surgical interventions, and improved accessibility to ophthalmic care...
PR Newswire
31/07/2025

Biopharmaceuticals Market is Estimated to Reach USD 948.6 Bilion by 2032 |…

Get a Free Sample Report - https://www.skyquestt.com/sample-request/biopharmaceuticals-market Get a Free Sample Report -https://www.skyquestt.com/sample-request/biopharmaceuticals-market Biopharmaceuticals Market Key Growth Drivers The global biopharmaceuticals sector is projected to grow at a rapid pace due to the increasing demand for targeted therapies, the increase in chronic diseases, and ongoing advances in biotechnology. One key driver of market growth is the rising...
PR Newswire
31/07/2025

Biosurgery Market is expected to generate a revenue of USD 25.64 Billion by…

The Biosurgery Market is witnessing a transformative phase, driven by increased surgical procedures, rising adoption of advanced hemostatic agents, and innovations in biomaterials. These trends are expected to shape future market dynamics. The Biosurgery Market is witnessing a transformative phase, driven by increased surgical procedures, rising adoption of advanced hemostatic agents, and innovations in biomaterials. These trends are expected to shape future market dynamics. Key Highlights...
PR Newswire
31/07/2025

Dia Group presents solid results, with a net profit of €38 million through June…

net profit of €38 million, reflecting strong momentum in Spain and solid performance in Argentina despite a challenging economic backdrop. The results show a strong start to the group’s new 2025-29 Strategic Plan, 'Growing every day' , which focuses on building sustainable, long-term value. Adjusted EBITDA at the consolidated levelincreased by 4% to 133 million euros,maintaining the margin on net sales at 4.7%.In termsof cash flow, at a consolidated level it reached98 million...
Nasdaq GlobeNewswire
31/07/2025

Unmind Announces $35M In New Funding to Transform Workplace Mental Health

"This new funding means we can accelerate our mission of unleashing human potential at work," said Dr. Nick Taylor, CEO and co-founder of Unmind. "We're excited to grow our impact and change the way companies approach mental health – blending expert care with smart technology to reach millions of people around the world." "This new funding means we can accelerate our mission of unleashing human potential at work," said Dr.Nick Taylor, CEO and co-founder of Unmind…
PR Newswire
31/07/2025

RESEARCH ADVANCES FROM THE 2025 ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE

Positive Results from the U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) Study The Alzheimer's Association U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) — a two-year, multi-site clinical trial testing two different lifestyle interventions in a representative population of older adults at risk for cognitive decline and dementia — found that both interventions improved cognition in older adults at…
PR Newswire
31/07/2025

Sales of Leqembi® totaled 23.1 billion yen in the second quarter 2025

BioArctic's report for the second quarter 2025 will be published on August 28 at 08:00 a.m. CET. BioArctic's report for the second quarter 2025 will be published onAugust 28at08:00 a.m. CET. This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact person below, onJuly 31, 2025, at12:00 CET. For further information, please...
PR Newswire
31/07/2025

MIND GAMES Expands Across the UK with Selfridges Rollout and Launch of Two…

Following its successful launch at Selfridges Oxford Street, MIND GAMES will expand into Selfridges Birmingham, Manchester Exchange, and Manchester Trafford in August 2025. In tandem, two standout fragrances—Kingside and Queenside—will be available for the first time in the UK, exclusively at Selfridges and Selfridges.com. Following its successful launch at Selfridges Oxford Street, MIND GAMES will expand into Selfridges Birmingham, Manchester Exchange, and Manchester Trafford in August 2025 ...
PR Newswire
31/07/2025

ESTEVE Acquires Regis Technologies, expanding U.S. presence and capabilities

This strategic move allows ESTEVE CDMO (actively operating under the Esteve Química brand) a physical presence in the United States, expanding its contract development and manufacturing solutions for innovative small-molecule active pharmaceutical ingredients (APIs) across the entire drug development lifecycle from pre-clinical to commercial manufacturing. This strategic move allows ESTEVE CDMO (actively operating under the Esteve Química brand) a physical presence inthe United States,...
PR Newswire
31/07/2025

OMRON Healthcare's Smart Devices Help Detect Early Heart Failure Risks in Over…

Logo1: https://kyodonewsprwire.jp/img/202507242643-O1-3Ei567mI Logo1:https://kyodonewsprwire.jp/img/202507242643-O1-3Ei567mI Logo2:https://kyodonewsprwire.jp/img/202507242643-O2-8OYa6KT8 Conducted in collaboration with Kyoto Prefectural University of Medicine, with support fromJapan'sMinistry of Economy, Trade and Industry (METI), the study examined how real-time sharing of patient data, including blood pressure, body weight, and electrocardiogram (ECG) readings, can detect...
PR Newswire
31/07/2025

Press Release: Q2: double-digit sales and solid business EPS growth. 2025 sales…

Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of rangeParis, July 31, 2025Q2 sales growth of 10.1% at CER 1and business EPS 2of €1.59Pharma launches increased sales by 39.8%, reaching €0.9 billion, driven by ALTUVIIIODupixent sales increased by 21.1% to €3.8 billion, supported by the COPD launchVaccines sales increased by 10.3% to €1.2 billionResearch and Development expenses were €1...
Nasdaq GlobeNewswire
31/07/2025

Pharming Group reports second quarter and first half 2025 financial results and…

Second quarter 2025 total revenues increased by 26% to US$93.2 million, compared to the second quarter 2024, driven by strong RUCONEST® and Joenja® revenue growthRUCONEST® second quarter revenue increased by 28% to US$80.4 million, compared to the second quarter 2024, reflecting strong growth in patients and prescribersJoenja® (leniolisib) second quarter revenue increased by 15% to US$12.8 million, compared to the second quarter 2024, with a further acceleration in patient uptake...
Nasdaq GlobeNewswire
31/07/2025

Fagron delivers strong performance with 11% topline growth and 12% increase in…

Regulated information - inside information Nazareth (Belgium)/Rotterdam (The Netherlands), 31 July 2025 – 7:00 AM CET Fagron delivers strong performance with 11% topline growth and 12% increase in REBITDA for H1 2025 Fagron, the leading global player in pharmaceutical compounding today publishes its first half results for the period ending 30 June 2025. Key Highlights Strong revenue performance with 10.9% reported revenue growth (14.4% at CER1) and 11.3% organic growth at...
Nasdaq GlobeNewswire
31/07/2025

Ipsen delivers strong results in the first half of 2025 and upgrades its…

H1 total sales growth of 11.4% at CER 1, or 9.7% as reported, driven by the three therapeutic areas: 95.7% in Rare Disease, 9.7% in Neuroscience, and 6.4% in OncologyH1 core operating income of €656m, growing by 21.9% as reported, with a core operating margin of 36.0% of total sales, increasing by 3.6 points Upgraded FY 2025 financial guidance 2 : total-sales growth greater than 7.0% at CER (prior guidance: greater than 5.0% at CER); core operating margin greater than 32.0% of total...
Nasdaq GlobeNewswire
31/07/2025

BioArtic: Latest data presented at AAIC 2025 reinforces lecanemab's clinical…

Of the patients who completed the core study, 95% chose to continue in the open-label extension study (OLE). Over three years of treatment, including both the core study and the OLE, lecanemab demonstrated 1.01 points less decline, measured by CDR-SB, compared to the Alzheimer's Disease Neuroimaging Initiative (ADNI)[i] cohort. This benefit became more pronounced after four years, with a less decline of 1.75 points. Similarly, when benchmarked against the expected decline in the BioFINDER[ii]…
PR Newswire
31/07/2025

Osteosarcoma Market on the Rise in the 7MM During the Forecast Period…

Key Takeaways from the Osteosarcoma Market Report Key Takeaways from the Osteosarcoma Market Report Discover the osteosarcoma new treatment @New Treatments for Osteosarcoma Osteosarcoma Market Dynamics The osteosarcoma market dynamics are expected to change in the coming years. Improvement of treatment over the years, along withnewly updated guidelines, the investigation of various immunotherapies such asPD-L1 and CTLA-4 inhibitors, and the exploration of genetic and...
PR Newswire
30/07/2025

Eviva Partners Launches New Think Tank, Exposes Attack on Aluminum-Containing…

Eviva and POH are grounded in three principles: Eviva and POH are grounded in three principles: On Sunday,MSNBC published an op-edby Morozov, leading vaccinologist Dr.Helen Petousis-Harrisand Eviva board member ProfessorStephan Lewandowsky. " Robert F. Kennedy Jr.and others … appear to be orchestrating a strategic attack on aluminum-containing vaccines," the op-ed says. But the science does not support aluminum as the culprit. In a major newstudyinvolving more than 1...
PR Newswire
30/07/2025

Spineway : H1 2025 results - Continued improvement in results and financial…

Press release Ecully, July 30, 2025 – 7 p.m. SPINEWAYH1 2025 results Continued improvement in results and financial positionFull-year 2025 growth target confirmedIn thousands of eurosConsolidated financial statements – UnauditedH1 2025H1 2024Revenue5,5736,535 Cost of sales(1,702)(2,059) Gross margin% of revenue3,87069%4,47668% Net operating expenses Of which general operating costs (5,068) ...
Nasdaq GlobeNewswire
30/07/2025

Global Market for Thyroid Gland Disorders Surges Amid Breakthroughs in…

This report provides a thorough overview of the global market for thyroid gland disorder diagnostics and treatments. It segments the market by disease type (such as hypothyroidism, hyperthyroidism, and thyroid cancer), as well as by product type, including diagnostics (blood tests, imaging, and procedures) and treatments (medications, surgeries, and therapies for thyroid eye disease). It also analyzes market distribution across end users like hospitals, clinics, pharmacies, research…
PR Newswire
30/07/2025

Oxurion Receives Amended Transparency Notification from Atlas Special…

Leuven, BELGIUM – July 30, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows: Oxurion received a transparency notification on July 29, 2025, from Atlas Special…
Actusnews Wire
30/07/2025

OXURION : Information on the Total Number of Voting Rights (Denominator)…

Atlas Special Opportunities, LLC has converted 12 convertible bonds in Oxurion resulting in a EUR 300,000 capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital Commitment[1] that will allow Oxurion to focus on developing innovative therapeutics to preserve the vision of elderly people, targeting potential…
Actusnews Wire
30/07/2025
Altri  Comunicati